Search
Learn how a novel drug is showing promise against lung and pancreatic cancer in early clinical trials by targeting the KRAS G12D mutation with a KRAS degrader.
MSK experts believe that giving the targeted drug asciminib to patients with chronic myeloid leukemia at the beginning of their treatment offers them a better chance of being cured.
Third-year students Oakley Olsen and Alison Spencer have been named Grayer Fellows. Fellows are chosen based on excellence demonstrated by their thesis proposal examinations.
Former leader of Memorial Sloan Kettering Paul Marks gives a compelling view of cancer research and treatment over the past 40 years in On the Cancer Frontier: One Man, One Disease, and a Medical Revolution.
New MSK research develops a new tool for studying mitochondrial DNA deletions; uncovers mechanisms of histiocytosis-associated neurodegeneration; and investigates how mutant stem cells co-opt regeneration to make tumors grow.
Recently, dozens of survivors, their parents, and members of the Memorial Sloan Kettering Cancer Center (MSK) Department of Pediatrics joined the Times Square Advertising Coalition to turn the bright lights of Times Square gold to raise awareness for pediatric cancer.
A Memorial Sloan Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates.
A new type of CAR T cell therapy for multiple myeloma could shorten the time to treatment.
The Genetics Society of America medal honored Dr. Anderson, Chair of the Developmental Biology Program, for her lifetime contributions to the science of genetics.
Kenneth Manotti has been named Senior Vice President and Chief Development Officer at Memorial Sloan Kettering Cancer Center (MSK).